Viracta Therapeutics Quote - VIRX

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

0.5437

Bid

0.544

Offer

0.6405

Volume

71,226

0.55 Day's Range 0.60

0.43 52 Week Range 1.68

Market Cap

21.6M

Previous Close

0.578

Open

0.5787

Last Trade

1000

0.5708

(formt)

Last Trade Time

Financial Volume

US$ 40,685

VWAP

0.571212

Average Volume (3m)

103,547

Shares Outstanding

39,272,434

Dividend Yield

PE Ratio

-0.42

Earnings Per Share (EPS)

-1.3

Revenue

Net Profit

-51.06M

Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein... Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. Its lead product candidate is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people who have received organ transplants. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.viracta.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

Viracta Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker VIRX. The last closing price for Viracta Therapeutics was US$0.58. Over the last year, Viracta Therapeutics shares have traded in a share price range of US$ 0.43 to US$ 1.68.

Viracta Therapeutics currently has 39,272,434 shares in issue. The market capitalisation of Viracta Therapeutics is US$21.60 million. Viracta Therapeutics has a price to earnings ratio (PE ratio) of -0.42.

Period †	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.0358	-6.17773943054	0.5795	0.649	0.55	56794	0.59957979	CS
4	-0.1373	-20.1615271659	0.681	0.8201	0.5	119499	0.59373998	CS
12	-0.4963	-47.7211538462	1.04	1.31	0.5	103547	0.77838955	CS
26	-0.0113	-2.03603603604	0.555	1.31	0.45	101899	0.7678853	CS
52	-0.9063	-62.5034482759	1.45	1.68	0.43	114416	0.81795536	CS
156	-10.8663	-95.2348816827	11.41	12.75	0.43	166230	3.12464024	CS
260	-16.2163	-96.7559665871	16.76	18.24	0.43	192821	4.78194597	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
LDROLode Resources Ltd	AUD 0.005 (400.00%)	49.26k
TKMOTrek Metals Limited	AUD 0.002 (100.00%)	277.78k
IBGOIronbark Zinc Limited	AUD 0.002 (100.00%)	1.25M
BFCBeston Global Food Company Limited	AUD 0.003 (50.00%)	8.94M
TD1Tali Digital Limited	AUD 0.0015 (50.00%)	1.05M
RAGORagnar Metals Limited	AUD 0.001 (-75.00%)	1M
ACMOAAustralian Critical Minerals Ltd	AUD 0.013 (-56.67%)	45k
AEVOAvenira Limited	AUD 0.001 (-50.00%)	3M
GRLOGodolphin Resources Limited	AUD 0.001 (-50.00%)	3M
HYTOHyTerra Ltd	AUD 0.011 (-35.29%)	1.2M
PENPeninsula Energy Ltd	AUD 0.1025 (0.00%)	77.12M
SYASayona Mining Limited	AUD 0.036 (-2.70%)	59.44M
ADNAndromeda Metals Limited	AUD 0.016 (-11.11%)	49.06M
IMUImugene Limited	AUD 0.057 (5.56%)	45.01M
SGRStar Entertainment Group Limited	AUD 0.50 (2.56%)	40.45M